Actonel Delayed-Release Back On Track With New PDUFA Date In October
This article was originally published in The Pink Sheet Daily
Executive Summary
Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.
You may also be interested in...
Prolia Pricing: Straddling Osteoporosis And Oncology
Amgen's first-in-class Prolia (denosumab) is burdened with a high price point as it joins the competitive and price-sensitive osteoporosis market. With a wholesale acquisition cost of $1,650 a year - including two $825 injections - Prolia will officially cost more than the leading branded drugs Actonel (risedronate), Boniva (ibandronate) and Reclast (zoledronic acid), and it will have to compete against generic versions of the gold standard, alendronate (Merck's Fosamax)
Manufacturing Issue Results in "Complete Response" Letter For Warner Chilcott Contraceptive
Warner Chilcott hopes to receive FDA approval for the low-dose product within six months.
Warner Chilcott Transformation Underway With Integration Of P&G's Pharma Biz
With the acquisition of Procter & Gamble's pharma business complete, the specialty drug maker adds 1,900 employees.